Phase II data presented at this year's AASLD meeting suggest all-oral, interferon-free regimens may be closer to becoming a reality than had been expected. For example,. Pharmasset Inc. (NASDAQ:VRUS) reported results from the Phase IIb ELECTRON trial that showed 100% of patients receiving PSI-7977 plus ribavirin for 12 weeks acheived a sustained virologic response 12 weeks after the end of treatment (SVR12). Below are selected data presented at the meeting for HCV candidates that companies are hoping to position as